QL1706
Clinical trials for QL1706 explained in plain language.
Never miss a new study
Get alerted when new QL1706 trials appear
Sign up with your email to follow new studies for QL1706, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Two-Pronged attack on breast cancer aims to spare hearts
Disease control Not yet recruitingThis study is testing a new two-in-one immunotherapy drug called QL1706, given with chemotherapy before surgery for early triple-negative breast cancer. The goal is to shrink tumors and see if some patients can safely skip a type of chemotherapy that can harm the heart long-term.…
Matched conditions: QL1706
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
New drug combo aims to shrink tumors before colon cancer surgery
Disease control Not yet recruitingThis study is testing whether adding a new two-drug immunotherapy (QL1706) to standard chemotherapy before surgery can help shrink tumors in people with a common type of stage III colon cancer. About 21 patients will receive the drug combination for about 3 months, followed by su…
Matched conditions: QL1706
Phase: PHASE2 • Sponsor: Qilu Hospital of Shandong University • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC